Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Published

Journal Article

CONTEXT: Incidence of end-stage renal disease due to hypertension has increased in recent decades, but the optimal strategy for treatment of hypertension to prevent renal failure is unknown, especially among African Americans. OBJECTIVE: To compare the effects of an angiotensin-converting enzyme (ACE) inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine), and a beta-blocker (metoprolol) on hypertensive renal disease progression. DESIGN, SETTING, AND PARTICIPANTS: Interim analysis of a randomized, double-blind, 3 x 2 factorial trial conducted in 1094 African Americans aged 18 to 70 years with hypertensive renal disease (glomerular filtration rate [GFR] of 20-65 mL/min per 1.73 m(2)) enrolled between February 1995 and September 1998. This report compares the ramipril and amlodipine groups following discontinuation of the amlodipine intervention in September 2000. INTERVENTIONS: Participants were randomly assigned to receive amlodipine, 5 to 10 mg/d (n = 217), ramipril, 2.5 to 10 mg/d (n = 436), or metoprolol, 50 to 200 mg/d (n = 441), with other agents added to achieve 1 of 2 blood pressure goals. MAIN OUTCOME MEASURES: The primary outcome measure was the rate of change in GFR; the main secondary outcome was a composite index of the clinical end points of reduction in GFR of more than 50% or 25 mL/min per 1.73 m(2), end-stage renal disease, or death. RESULTS: Among participants with a urinary protein to creatinine ratio of >0.22 (corresponding approximately to proteinuria of more than 300 mg/d), the ramipril group had a 36% (2.02 [SE, 0.74] mL/min per 1.73 m(2)/y) slower mean decline in GFR over 3 years (P =.006) and a 48% reduced risk of the clinical end points vs the amlodipine group (95% confidence interval [CI], 20%-66%). In the entire cohort, there was no significant difference in mean GFR decline from baseline to 3 years between treatment groups (P =.38). However, compared with the amlodipine group, after adjustment for baseline covariates the ramipril group had a 38% reduced risk of clinical end points (95% CI, 13%-56%), a 36% slower mean decline in GFR after 3 months (P =.002), and less proteinuria (P<.001). CONCLUSION: Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria.

Full Text

Duke Authors

Cited Authors

  • Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S; African American Study of Kidney Disease and Hypertension (AASK) Study Group,

Published Date

  • June 6, 2001

Published In

Volume / Issue

  • 285 / 21

Start / End Page

  • 2719 - 2728

PubMed ID

  • 11386927

Pubmed Central ID

  • 11386927

International Standard Serial Number (ISSN)

  • 0098-7484

Digital Object Identifier (DOI)

  • 10.1001/jama.285.21.2719

Language

  • eng

Conference Location

  • United States